Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold

Executive Summary

Approval of the first pegfilgrastim biosimilars in the EU would mark the start of a period of accelerated sales declines for Amgen's Neulasta but the outlook for the blockbuster bio-originator is not necessarily bleak.

Advertisement

Related Content

Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
Keeping Track: FDA Starts November With A Bang
CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due
CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
EU First For Pegfilgrastim Biosimilars? EMA Decides This Week
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
Apotex Bags First Biosimilar Neulasta, Plans To Undercut Amgen In Canada By 25%

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel